An increasing number of clinically unique disease-modifying therapies (DMTs) have been approved for the treatment of relapsing forms of multiple sclerosis (MS), the most prevalent form of MS. Nevertheless, all approved drugs present clinical shortcomings in efficacy, safety, tolerability, and/or delivery, creating opportunities for new and improved alternatives. This content provides quantitative insight into U.S. and European physicians’ perceptions of key treatment drivers and goals in the management of relapsing forms of MS and the current level of unmet need in this area. We analyze the commercial opportunities and how emerging therapies may capitalize on these opportunities, with a subfocus on next-generation oral DMTs in our conjoint-based Target Product Profile simulator.
Unmet Need provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.
Markets covered: United States, United Kingdom, France, Germany.
Primary research: Survey of 60 U.S. and 30 European neurologists fielded in December 2017.
Key companies: Biogen, Novartis, Teva, Roche, Merck, Sanofi/Genzyme.
Key drugs: Gilenya, Aubagio, Tecfidera, Copaxone, Avonex, Tysabri, Ocrevus, Mavenclad.
Key metrics included: